Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Median Technologies

< Previous 1 2 Next >
Median Technologies Files European Application for Class IIb CE Marking of Its AI-Based Software as a Medical Device for Lung Cancer Screening, eyonis® LCS
From Median Technologies
Via Business Wire
Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025
From Median Technologies
Via Business Wire
Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS
From Median Technologies
Via Business Wire
Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025
From Median Technologies
Via Business Wire
Median Technologies Reports Full-year 2024 Financial Results
From Median Technologies
Via Business Wire
Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements
From Median Technologies
Via Business Wire
eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study
From Median Technologies
Via Business Wire
Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference
From Median Technologies
Via Business Wire
Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
From Median Technologies
Via Business Wire
Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions
From Median Technologies
Via Business Wire
Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook
From Median Technologies
Via Business Wire
Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU
From Median Technologies
Via Business Wire
Median Technologies: Financial Communications Schedule for the First Half of 2025
From Median Technologies
Via Business Wire
Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024
From Median Technologies
Via Business Wire
Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis™ Lung Cancer Screening (LCS) REALITY Data
From Median Technologies
Via Business Wire
Median Technologies to Host Key Opinion Leader (KOL) Webinar on AI and Lung Cancer Screening
From Median Technologies
Via Business Wire
Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results
From Median Technologies
Via Business Wire
Median Technologies to Attend and Present at the ESMO Congress 2024, Being Held in Barcelona, Spain, from Sept 13-17, 2024
From Median Technologies
Via Business Wire
Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software as medical device at the IASLC 2024 World Conference on Lung Cancer
From Median Technologies
Via Business Wire
Median Technologies to host two webcasts on September 5, 2024
From Median Technologies
Via Business Wire
Median Technologies Announces Pivotal REALITY Study of Its eyonis™ LCS Lung Cancer Diagnostic Met All Primary and Secondary Endpoints
From Median Technologies
Via Business Wire
Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery
From Median Technologies
Via Business Wire
Median Technologies Reports Record iCRO Backlog, eyonis™ LCS On-Track for Standalone Pivotal Study Readout in August
From Median Technologies
Via Business Wire
Median Technologies: Disclosure of total number of voting rights and number of shares in the capital as of May 31st, 2024
From Median Technologies
Via Business Wire
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 19, 2024
From Median Technologies
Via Business Wire
Median Technologies to Participate in the 2024 ASCO Annual Meeting, May 31 - June 4, 2024, McCormick Place, Chicago, IL, USA
From Median Technologies
Via Business Wire
Median Technologies, a World Leading Oncology Clinical Trial Imaging Services Provider, Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company
From Median Technologies
Via Business Wire
Median Technologies Reports Full-year 2023 Financial Results and Provides First Quarter 2024 Financial Information
From Median Technologies
Via Business Wire
Median Technologies to Participate in the TD Cowen’s 44th Annual Health Care Conference
From Median Technologies
Via Business Wire
Median Technologies to Participate and Speak at the 2024 European Congress of Radiology (ECR), February 28 – March 3, Vienna, Austria
From Median Technologies
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.